Kaival Brands (KAVL) Line of BidiVapor Products Accepted by FDA Premarket Tobacco Product Application...
Kaival Brands Innovation Group Inc. (OTCMKTS: KAVL) ripped to an all time high of $3.65 last week after announcing FDA Premarket Tobacco Product Application...
The Public Companies Leading the Digital Transformation in the Way We Shop, Work, and...
Billion dollar industries springing up overnightThe New Digital GoldMulti-decade Multi-Trillion dollar MegaTrend emergingVideo is the New Voice and All Roads Lead to ARApple is...
Kaival Brands (KAVL) Where There’s Smoke There’s Fire
This new partnership with Hackney represents Kaival Brands' largest single distribution agreement to date. In 2020, the Bidi® Stick was available in approximately 10,000 stores and this partnership will potentially place Bidi Vapor products in 35,000 stores across the United States
Emerging Growth Report on Nextech AR Solutions (NEXCF)
As a pure-play augmented reality investment, NEXCF stock offers years of technological relevance.
What do fighter pilots, furniture shoppers, neurosurgeons and sports fans settling down...
CytoDyn Update Reveals Q1 Sales Pipeline, Philippine EUA, NASDAQ Uplisting, & High Likelihood of...
CytoDyn Inc. (OTCMKTS: CYDY) may have given one of its last updates as an OTC company yesterday and revealed a number of positive surprises. They could be saying hello NASDAQ, and hello EUA in the course of the next couple of weeks.
BuyersStrike Short Attack Ahead of NASDAQ Uplisting
This morning shares of CytoDyn Inc. (OTMKTS: CYDY) screamed higher in very active trading and touched $7.00 per share to a $4.14 billion market...
Mesoblast Crashed on Poor DSMB Report Leaving CytoDyn as Sole Survivor in COVID-19 Therapeutics
Only Mesoblast (NASDAQ:MESO) and CytoDyn Inc. (OTCMKS: CYDY) had mortality as a primary endpoint in severe to critical COVID-19.
Cracking the FDA Code to COVID-19 Approvals
100% correlation between this list and an EUA approval5 drug candidates on the list have not received an EUA3 drug candidates seem imminent
What this...
Rapid Countermeasure Against COVID-19: Therapeutics Not Vaccines
In the interim, no patients can get the drug via emergency IND because the FDA has stopped that access. This is a point of moral outrage. By not looking at the interim data for leronlimab in an urgent fashion the FDA is condemning thousands of people to death daily.
Emerging Growth Report; First Graphene (ASX: FGR) Is on the Cusp of Innovation That’s...
First Graphene, in a partnership with newGen Group, forwarded graphene solutions to Rio Tinto (ASX: RIO) and BHP Group (ASX: BHP)
Latest News
NexTech AR Solutions Corp. Announces First Quarter 2021 Earnings and Conference...
Miami, FL–(May 7, 2021) – EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging...
